Results 181 to 190 of about 276,101 (206)

Ferroptosis in hematological malignancies: molecular mechanisms and therapeutic potential. [PDF]

Cell Oncol (Dordr)
Liu J, Liu R, Miao J, He A.
europepmc   +1 more source

Role of microRNAs in hematological malignancies research: A bibliometric analysis. [PDF]

Medicine (Baltimore)
Abdullah SM.
europepmc   +1 more source

Pharmacist-led interventions in hematological malignancies: a systematic review of clinical, process and economic outcomes. [PDF]

Front Pharmacol
Mohamed A, Salman B, Al Maskari R, Al-Farsi K, Yassin MA.   +4 more
europepmc   +1 more source

HLA-G in Hematological Malignancies: Immunoregulatory Mechanisms and Implications for Immune Evasion and Immunotherapy. [PDF]

J Immunol Res
Ribeiro TLCP, Nogueira GM, Souza-Barros M, Moraes JS, Santos LS, Oliveira LS, Crespo-Neto JA, Ghedini JGS, Magalhães-Gama F, Malheiro A, Alves-Hanna FS, Costa AG.   +11 more
europepmc   +1 more source

Sex Differences in Cancer and Cardiotoxicity: Mechanisms, Outcomes, and Clinical Implications Across Solid and Hematological Malignancies. [PDF]

Cancers (Basel)
Keramida K, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Dent S, Drakaki A, Fuster JJ, Mamas MA, Okwuosa T, Scarfo L, Van Der Meer P, Yang EH, Lopez-Fernandez T.   +13 more
europepmc   +1 more source

Distribution characteristics and influencing factors of active cytomegalovirus infection in patients with hematological malignancies complicated with sepsis. [PDF]

Eur J Clin Microbiol Infect Dis
Chen B, Li S, Shu W, Le J, Wang X, Ma X, Wei G, Feng Q, Li Q, Li X, Jin D.   +10 more
europepmc   +1 more source

Intestinal Microbes and Hematological Malignancies

Cancers, 2023
Hematological malignancies are diverse, with high malignancy characteristics, poor prognoses, and high mortality rates. The development of hematological malignancies is driven by genetic factors, tumor microenvironment factors, or metabolic factors ...
Qin Yang, Yinghong Zhu
exaly   +2 more sources

CAR T-Cell Therapy in Hematological Malignancies

International Journal of Molecular Sciences, 2021
Chimeric antigen receptor (CAR) T-cells (CAR T-cells) are a promising therapeutic approach in treating hematological malignancies. CAR T-cells represent engineered autologous T-cells, expressing a synthetic CAR, targeting tumor-associated antigens (TAAs)
Roland Geisberger, Richard Greil, Theresa Haslauer   +2 more
exaly   +2 more sources

Novel Immunotherapies for Hematological Malignancies

Current Molecular Pharmacology, 2016
The successful treatment of hematological malignancies remains challenging. Prognosis is often dismal given the frequency of disease relapse or treatment refractory disease.
Hong Zheng
exaly   +2 more sources

Recent Progress of Exosomes in Hematological Malignancies: Pathogenesis, Diagnosis, and Therapeutic Strategies [PDF]

International Journal of Nanomedicine
Hu Zhang,1,* Jingyi Xia,2,* Xueqing Wang,1 Yifan Wang,2 Jie Chen,3 Lin He,1 Jingying Dai2 1Department of Pharmacy, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science ...
Jingying Dai
exaly   +1 more source